Stockreport

Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]

Elevation Oncology, Inc. - Common stock  (ELEV) 
PDF G&A Expenses : G&A expenses were down to $14.9 million for the full year 2023 from $15.8 million in 2022. Net Loss : ELEV reported a net loss of $7.9 million for Q4 2 [Read more]